Assess whether a CMC change is a comparability or a new product (a5b4a1)

Situation

A boxed-warning proposal from the review division put complete-response-letter deficiency list in front of labeling negotiator in a company with a CMC site change mid-review. This Pharma & Life Sciences / Pharmacovigilance close is a CMC change is from complete-response-letter deficiency list, and the live options are A CMC change is a comparability, A new product.

Decision

Labeling negotiator in a company with a CMC site change mid-review must choose A CMC change is a comparability / A new product using complete-response-letter deficiency list after a boxed-warning proposal from the review division.

Hypotheses to test

• A boxed-warning proposal from the review division is noise around an already-controlled Pharmacovigilance process in a company with a CMC site change mid-review, given complete-response-letter deficiency list.
• A boxed-warning proposal from the review division is the event in complete-response-letter deficiency list that forces A CMC change is a comparability for labeling negotiator under Pharma & Life Sciences.
• Complete-response-letter deficiency list shows a one-file miss after a boxed-warning proposal from the review division, not a Pharmacovigilance program failure.
• Complete-response-letter deficiency list cannot decide a CMC change is yet after a boxed-warning proposal from the review division; hold is the only Pharma & Life Sciences close a company with a CMC site change mid-review can defend.

Analysis required

• Check whether complete-response-letter deficiency list supports the labeled claim labeling negotiator would keep.
• Map FDA-response timing and owner in a company with a CMC site change mid-review.
• Trace CMC, labeling, or pharmacovigilance facts in complete-response-letter deficiency list after a boxed-warning proposal from the review division.
• For this Pharma & Life Sciences Pharmacovigilance file, read complete-response-letter deficiency list against a boxed-warning proposal from the review division and write the one fact that would move a CMC change is for labeling negotiator.

Recommendation

Choose A CMC change is a comparability / A new product on this Pharma & Life Sciences / Pharmacovigilance packet (complete-response-letter deficiency list after a boxed-warning proposal from the review division). Lead with the Pharma & Life Sciences option complete-response-letter deficiency list can support after a boxed-warning proposal from the review division, then the two facts that force it, then the Monday action for labeling negotiator in a company with a CMC site change mid-review.